key: cord-0961136-jv42tm89
authors: Cai, Shuhan; Zhu, Fangfang; Hu, Hongtao; Xiang, Hui; Wang, Dawei; Wang, Jing; Li, Lu; Yang, Xiao; Qin, Aihua; Rao, Xin; Luo, Yun; Li, Jianguo; Kashani, Kianoush B.; Hu, Bo; Peng, Zhiyong
title: Assessment of respiratory support decision and the outcome of invasive mechanical ventilation in severe COVID-19 with ARDS
date: 2022-02-03
journal: Journal of Intensive Medicine
DOI: 10.1016/j.jointm.2021.12.003
sha: 8a81a7fdd365d5f5ebed66f84774e7cec2b55127
doc_id: 961136
cord_uid: jv42tm89

Background The coronavirus disease 2019 (COVID-19) is an ongoing pandemic since December 2019. Invasive mechanical ventilation (IMV) is essential for the management of COVID-19 with acute respiratory distress syndrome (ARDS). We aimed to assess the impact of compliance with a respiratory decision support system on the outcomes of patients with COVID-19-associated ARDS who required IMV. Methods In this retrospective, single-center, case series, 46 patients with COVID-19-associated ARDS who required IMV at Zhongnan Hospital of Wuhan University, China, from January 8, 2020, to March 24, 2020, with the final follow-up date of April 20, 2020, were included. Demographic, clinical, laboratory, imaging, and management information were collected and analyzed. Compliance with the respiratory support decision system was documented, and its relationship with 28-day mortality was evaluated. Results The median age of the 46 patients with COVID-19-associated ARDS requiring IMV was 68.5 years, and 31 were men. The partial pressure of arterial oxygen (PaO2)/fraction of inspired oxygen (FiO2) ratio at intensive care unit (ICU) admission was 104 mmHg. The median total length of IMV was 12.0 (interquartile range [IQR], 6.0–27.3) days, and the median respiratory support decision score was 11.0 (IQR, 7.8–16.0). To 28 days after ICU admission, 18 (39.1%) patients died. Survivors had a significantly higher respiratory support decision score than non-survivors (15.0 [10.3–17.0] vs. 8.5 (6.0–10.3), P = 0.001). Using receiver operating characteristic (ROC) curve to assess the discrimination of respiratory support decision score to 28-day mortality, the area under the curve (AUC) was 0.796 (95% confidence interval [CI]: 0.657–0.934, P = 0.001) and the cut-off was 11.5 (sensitivity = 0.679, specificity = 0.889). Patients with a higher score (>11.5) were more likely to survive at 28 days after ICU admission (log-rank test, P < 0.001). Conclusions For severe COVID-19-associated ARDS with IMV, following the respiratory support decision and assessing completion would improve the progress of ventilation. With a decision score of >11.5, the mortality at 28 days after ICU admission showed an obvious decrease.

The coronavirus disease 2019 caused by severe acute respiratory coronavirus 2 (SARS-CoV-2) in an ongoing pandemic. Although most of the cases were mild, about 20% deteriorated and developed severe pneumonia and acute respiratory distress syndrome (ARDS), which has led to millions of deaths. Patients with COVID-19 pneumonia present with dyspnea, high respiratory drive, and severe hypoxemia, eventually complicated with multiorgan dysfunction and death. [1, 2] Invasive mechanical ventilation (IMV) is considered an essential supportive tool for patients with COVID-19-associated ARDS. Overall, 71-88% of patients with COVID-19-associated ARDS admitted to the intensive care unit (ICU) received IMV. [3] [4] [5] While IMV is used to provide respiratory support, [6, 7] it may result in lung damage due to barotrauma, volutrauma, and atelectrauma [8, 9] lead to ventilator-associated pneumonia. [10] Even with similar IMV management strategies, the incidence of mortality among patients requiring IMV is variable. While high mortality rates were reported from China (81%) [4] and New York City (88.1%), [5] relatively lower mortality was noted in the Lombardy region of Italy (26-35%) . [3] To further clarify these controversial reports, we aimed to assess the impact of a standardized respiratory support decision system with its associated scoring tool on the mortality of patients with COVID-19-associated ARDS requiring IMV. [11] Methods

This retrospective study was conducted at the Zhongnan Hospital of Wuhan University, Hubei, China, which was a designated COVID-19 hospital by the Chinese government. The Zhongnan Hospital of Wuhan University ethics committee approved the study (No. 2020011) . Given the observational retrospective nature of the study, the need for written informed consent from each patient was waived.

We retrospectively analyzed all consecutive adult patients (≥18 years) with COVID-19-associated ARDS who required IMV from January 8, 2020, to March 24, 2020 . During the treatment period, COVID-19 was diagnosed by both chest CT scan and real-time reverse transcription-polymerase chain reaction. Patients with COVID-19-associated ARDS were managed according to the previous ARDS and sepsis guidelines, as well as references for ARDS and IMV. [12] [13] [14] Patients who stayed in the ICU for <24 h were excluded.

We reviewed the clinical electronic medical records and nursing notes for all enrolled patients. The recorded data included demographics, medical history, underlying comorbidities, complications, radiological examinations, vital signs, laboratory test results, medications, need for the high-flow nasal cannula (HFNC) or non-invasive ventilation (NIV), mechanical ventilator settings, use of neuromuscular blockers (NMBAs) or prone positioning, need for extracorporeal membrane oxygenation (ECMO), and the 28-day mortality after ICU admission (28d-ICU). The Acute Physiology and Chronic Health Evaluation II (APACHE II) score was calculated on the day of ICU admission, and the Sequential Organ Failure Assessment score (SOFA) was assessed both on the day of ICU admission and at intubation. Lung injury score (LIS) was recorded according to the scoring system proposed by Murray et al [15] on the day of ICU admission. The date of disease onset was defined as the day when the symptoms of COVID-19 started. ARDS was judged based on the Berlin definition. [16] The total length of non-invasive devices (i.e., HFNC or NIV) before the initiation of IMV was defined as the total duration of HFNC and NIV from the day of use to the time of intubation. The total length of mechanical ventilation was counted from the day of intubation to the day of weaning from the ventilator or death.

The respiratory support decision protocol was an evidence-based protocol that relied on the Surviving Sepsis Campaign: Guidelines on the Management of Critically Ill Adults with Coronavirus Disease 2019 [17] and other current references for ARDS and IMV. Physicians SC, LL, XY, and BH screened the guidelines and references and designed the protocol. Then, the entire team discussed and revised the protocol in three rounds until consensus was achieved. The final protocol is described in Figure 1 .

In the absence of life-threatening hypoxemia and severe respiratory distress, respiratory support was initiated with HFNC or NIV. The use of non-invasive respiratory support continued if hypoxemia and respiratory distress symptoms improved within 2 h (SPO 2 > 92%, Vt < 9 mL/kg, respiratory rate [RR] < 30 times/min) [18, 19] with fraction of inspired oxygen (FiO 2 ) <70%. Otherwise, endotracheal intubation and IMV were required.

In the presence of life-threatening hypoxemia or severe respiratory distress, emergency endotracheal intubation and IMV were recommended. The IMV setting was based on the lung-protective strategy, [11, 20, 21] including low tidal volume (TV) ( To evaluate the quality and completion of the provided respiratory support, we designed a scoring system according to the critical parts of the respiratory support protocol [ Table 1 ]. [18, 19, 22, 24, 25] Nine items used in this tool provided a range of scores from 6 to 18 points. For each respiratory decision, a certain period of observation and management was permitted before the score was calculated by two groups (FZ and HX vs. HH and JW). If the calculated scores were different between the two groups, SC and BH assigned the final score for each patient.

Categorical variables were summarized as counts and percentages. Proportions for categorical variables were compared using the chi-squared and Fisher's exact tests, as appropriate. Continuous variables were summarized as mean ± standard deviation when the data were normally distributed, and the groups were compared by Student's t-test; otherwise, median and interquartile range (IQR) were used, and the Mann-Whitney U test was used to examine differences between the groups. Univariate logistic regression analysis was performed for all known factors that could be associated with 28d-ICU in COVID-19 patients, including demographics, underlying diseases, and decision score. We used a univariate Cox regression analysis for all factors that could be associated with the 28d-ICU, including demographics, SOFA and APACHE II scores, and the respiratory decision score. A receiver operating characteristic (ROC) curve was generated to detect the best discriminative variable of 28d-ICU in COVID-19 patients. The area under the curve (AUC) and the Youden index were calculated for the 28d-ICU. A two-sided α of <0.05 was considered statistically significant. All statistical analyses were performed using the Statistical Package for the Social Sciences (version 26.0, IBM Corporation, Armonk, NY, USA).

The study cohort included 46 

At ICU admission, the heart rate (HR) (median: 99.0, IQR [84. 8-109.8] ) and RR Table 3 ].

Thirty (65.2%) patients received HFNC, and 26 (56.5%) individuals were on NIV before intubation. The length of HFNC and NIV before intubation was 53 (IQR: 0-180) h, and the time from hospital admission to intubation was 4.0 (IQR: 1.5-9.5) days. After intubation, the initial IMV settings were FiO 2 75% (IQR: 50-100%), tidal volume (Vt) 6.0 (IQR: 5.8-6.0) mL/kg of ideal body weight, and PEEP 10 (IQR: Table 4 ].

Compare to non-survivors at 28-day after ICU admission, survivors had the following non-significant trends: (1) Table 4 ].

Among all included patients, the median respiratory support decision score was 11.0 (IQR, 7.8-16.0). At 28d-ICU, the decision score was significantly higher in survivors Table 5 ].

Using the ROC curve to assess the performance of respiratory support decision score in prediction of 28d-ICU, the AUC was 0.796 (95% CI: 0.657-0.934, P = 0.001) and the cut-off was 11.5 (sensitivity = 0.679, specificity = 0.889) [ Figure 3A ]. We divided the entire cohort into two groups based on the respiratory support decision score cut-off of 11.5 (>11.5 group included 21 patients, and <11.5 group included 25 patients). The >11.5 group had lower 28d-ICU than the <11.5 group (9.5% vs. 64%, P < 0.001), but had non-significant differences in clinical characteristics (age, APACHE II, SOFA, and LIS) and intervention (total length of HFNC + NIV, total length of IMV, interval between hospital admission, and IMV) [Supplementary Table   2 ]. Patients with a higher score (>11.5) were more likely to survive 28 days after ICU admission (log-rank test, P < 0.001) than those with a lower score (<11.5) [ Figure   3B ].

In this retrospective study, we assessed the quality of implementation of a respiratory support decision system and provided an assessment score for evaluating such quality in patients with COVID-19-associated ARDS who required IMV. For these patients, compliance with the respiratory support decision and implementation of the assessment score was associated with improvement in the ventilation process.

IMV is usually considered a supportive management strategy and is often life-saving for patients with respiratory failure. However, the risk associated with IMV, especially ventilator-induced lung injury (VILI) [26] [27] [28] and right heart strain resulting from acute cor-pulmonale secondary to ARDS [29, 30] should be considered.

In this study, we reported the implementation of a respiratory support decision system based on the current level of evidence and best practices for the management of respiratory failure in COVID-19-associated ARDS. [31] [32] [33] IMV should be implemented as a rapid and efficient respiratory support method for life-threatening respiratory failure. Protective ventilation strategy including low Vt (4-8 mL/kg), [34, 35] restricted plateau pressure (≤30 cmH 2 O), [36] a driving pressure (<15 cmH 2 O), and appropriate PEEP for the static lung compliance was applied in the IMV management to minimize VILI among patients enrolled in our study. [37] Alveolar salvage therapies, the use of NMBAs, [38] and prone positioning [39] [40] [41] should be considered for the patients with PaO 2 /FiO 2 ≤ 150 mmHg and in the early stages of ARDS. Because RM may directly over distend aerated lung units and could, paradoxically, lead to increased VILI or alter hemodynamic status, the use of RMs should be only limited to appropriate cases among ARDS patients. [42] In a randomized clinical trial, the authors showed that in patients with moderate-to-severe ARDS, the 28-day all-cause mortality was higher in lung recruitment and titrated PEEP group in comparison with the low PEEP group. [43] Assessment of lung recruitability should be performed before RM, so RM and titrated PEEP can only be used among those with recruitment potential. Extracorporeal lung support therapies are also viable options to protect the lungs, while the key question is how to balance the trade-offs between patient self-inflicted lung injury (P-SILI), the complications of extracorporeal circuits, and the side effects of IMV. [6] When the optimal lung-protective strategy and alveolar salvage therapy are found ineffective, ECMO should be considered. [44] The prolonged use of HFNC or NIV in the presence of strong respiratory drive may lead to P-SILI among COVID-19-associated ARDS patients. [45] Frat et al [19] found that under standard oxygen therapy, patients with a RR ≥30 breaths/min were more likely to need intubation than patients with a RR <30 breaths/min. For NIV, a PaO 2 /FiO 2 ratio <200 mmHg and a TV of >9 mL/kg of predicted body weight were independent predictors of intubation. [19] To assess compliance with the respiratory support decision system, an evaluation score tool was designed based on respiratory support and cardiopulmonary protection principles. The items in the tool were chosen to assess the effect of different oxygen supplement therapies, controlling respiratory drive, intubation timing, and initiation of ECMO. Limitations in resources may delay the implementation of the respiratory support decision system and its assessment, as observed in our study (6-12 h Table 1 ]. This may indicate that clinical providers considered these codes as clinically critical. While nearly 40% of patients were at risk of acute cor-pulmonale due to hypercarbia (code M), [44] it was not an independent risk factor for death in this cohort. Table 1; Table 5 ]. Maintaining SpO 2 by using high oxygen concentration (FiO 2 > 0.7) may lead to hyperoxic acute lung injury [46] (code C). In a recent study, in patients with ARDS, early exposure to a conservative-oxygenation strategy with an SPO 2 between 88% and 92% did not increase the 28d-ICU, when compared with maintaining the SPO 2 ≥ 96%. [47] In the lung-protective mechanical ventilation strategy, although low TV ventilation was implemented for all the patients, the plateau pressure was >30 cmH 2 O (code H) in 50% of patients, and >60% of the patients had driving pressure >15 cmH 2 O (code I). In other studies, similar relationships have been reported. [48, 49] Only 34.8% of patients had lung compliance of >30 mL/cmH 2 O after 48 h of IMV (code N). As the median PaO 2 /FiO 2 ratio of these patients was only 113 mmHg (IQR: 83.9-177.7), all patients with a PaO 2 /FiO 2 ratio <150 mmHg received NMBAs, yet 39.1% of the cases did not achieve code J due to late initiation of NMBAs. In patients with poor lung compliance, conventional alveolar salvage therapy did not protect the lungs; thus, initiating ECMO (code O) and resting lung during ECMO (code P) were found to be independently associated with a lower risk of death.

In this research, we used three codes (i.e., R, S, and T) that were deducted from the total score. Thirteen patients (five survivors and eight non-survivors) had a history of SO 2 < 80% for >6 h during hospitalization, and seven patients (two survivors and five non-survivors) had non-effective RMs or improper PEEP level during IMV. A randomized clinical trial showed that in patients with moderate-to-severe ARDS, a strategy with lung recruitment and titrated PEEP compared with low PEEP increased the 28-day all-cause mortality. [43] The absence of statistical differences in our study might be because of the small sample size. Tables 2-5 , there were no differences in most parameters between survivors and non-survivors except for some respiratory decision support system scores. The patients included in this study, regardless of survival status, were generally older and critically ill when admitted to ICU. As shown in Table 3 , all patients had a Murray LIS of >3, with median APACHE II and SOFA scores of 20 and 7, respectively, for survivors, and median APACHE II and SOFA scored of 19 and 7 for non-survivors, respectively. In the early period of the pandemic, uncertainty and non-standard treatment were common; therefore, the completion of some critical details in the respiratory decision support system was crucially important and might be able to influence patient's clinical outcomes.

According to the ROC curve and respiratory support decision score with a cut-off of 11.5 as an independent risk factor of the 28d-ICU, complying with the protocolized respiratory support decision system process to improve the quality of respiratory support could potentially reduce the risk of death among patients with COVID-19-associated ARDS who require IMV, particularly in resource-limited settings.

Our study has some limitations. This was a single-center retrospective study with a small sample size, which may limit its generalizability and conclusions. For the same reason, we are not able to imply any causal relationship as our findings are solely associations. Hence, prospective studies with large sample sizes are required to verify our results. Because SARS-CoV-2 is a relatively new virus, some items of our standard scoring system were mostly based on experts' opinions and lacked evidence-based medical support.

For patients with COVID-19-associated ARDS who required IMV, complying with and implementing the respiratory support decision system can likely improve the ventilation process. The mortality at 28 days after ICU admission was lower with a decision score of >11.5 than with a decision score <11.5. 

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. P values indicate differences between survivors and non-survivors. P < 0.05 was considered statistically significant. P values indicate differences between survivors and non-survivors. P < 0.05 was considered statistically significant. 

Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus

Clinical characteristics of coronavirus disease 2019 in China

Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy Region, Italy

Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: A single-centered, retrospective, observational study

Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City Area

Mechanical ventilation to minimize progression of lung injury in acute respiratory failure

Respiratory drive in the acute respiratory distress syndrome: Pathophysiology, monitoring, and therapeutic interventions

Impact of spontaneous breathing during mechanical ventilation in acute respiratory distress syndrome

Unrecognized suffering in the ICU: Addressing dyspnea in mechanically ventilated patients

Prevention of early ventilator-associated pneumonia after cardiac arrest

Respiratory support in COVID-19 patients, with a focus on resource-limited settings

The surviving sepsis campaign bundle

Update

Guidelines on the management of acute respiratory distress syndrome

European Society of Intensive Care Medicine/Society of Critical Care Medicine Clinical Practice Guideline: Mechanical ventilation in adult patients with acute respiratory distress syndrome

An expanded definition of the adult respiratory distress syndrome

Acute respiratory distress syndrome: The Berlin definition

Surviving sepsis campaign: Guidelines on the management of critically ill adults with coronavirus disease 2019 (COVID-19)

An index combining respiratory rate and oxygenation to predict outcome of nasal high-flow therapy

Predictors of intubation in patients with acute hypoxemic respiratory failure treated with a noninvasive oxygenation strategy

Clinical management of severe acute respiratory infection ( SARI) when COVID-19 disease is suspected: interim guidance

Surviving sepsis campaign: Guidelines on the management of critically ill adults with coronavirus disease 2019 (COVID-19)

Extracorporeal life support for adults with respiratory failure and related indications: A review

Contemporary management of cardiogenic shock: A scientific statement from the American Heart Association

American Heart Association Guidelines Update for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care

Respiratory support in COVID-19 patients, with a focus on resource-limited settings

Injurious ventilatory strategies increase cytokines and c-fos m-RNA expression in an isolated rat lung model

Ventilator-induced lung injury: Lessons from experimental studies

Ventilator-induced lung injury

Pathophysiology and pharmacological treatment of pulmonary hypertension in acute respiratory distress syndrome

Acute cor pulmonale during protective ventilation for acute respiratory distress syndrome: Prevalence, predictors, and clinical impact

Respiratory management in severe acute respiratory syndrome coronavirus 2 infection

Management of respiratory failure due to COVID-19

Management of COVID-19 respiratory distress

Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome

Low tidal volume versus non-volume-limited strategies for patients with acute respiratory distress syndrome. A systematic review and meta-analysis

Potentially modifiable factors contributing to outcome from acute respiratory distress syndrome: The LUNG SAFE study

Experts' opinion on management of hemodynamics in ARDS patients: Focus on the effects of mechanical ventilation

Neuromuscular blockers in early acute respiratory distress syndrome

Prone positioning in patients with moderate and severe acute respiratory distress syndrome: A randomized controlled trial

Prone position for acute respiratory distress syndrome. A systematic review and meta-analysis

Treatment of ARDS with prone positioning

Lung morphology predicts response to recruitment maneuver in patients with acute respiratory distress syndrome

Effect of lung recruitment and titrated positive end-expiratory pressure (PEEP) vs low PEEP on mortality in patients with acute respiratory distress syndrome: A randomized clinical trial

Rationale and description of right ventricle-protective ventilation in ARDS

Clinical consensus recommendations regarding non-invasive respiratory support in the adult patient with acute respiratory failure secondary to SARS-CoV-2 infection

Hyperoxic acute lung injury

Liberal or conservative oxygen therapy for acute respiratory distress syndrome

Contemporary ventilator management in patients with and at risk of

Protective mechanical ventilation in United Kingdom critical care units: A multicentre audit

Figure 1: The respiratory support treatment process of adult severe COVID-19 patients. COVID-19: Coronavirus disease 2019; ECMO: Extracorporeal membrane oxygenation; FiO 2 : Fraction of inspired oxygen

NIV: Non-invasive ventilation; PaCO 2 : Artery partial pressure of carbon dioxide

Data expressed as median (IQR) and n (%)

P values indicate differences between survivors and non-survivors. P < 0.05 was considered statistically significant

Acute Physiology and Chronic Health Evaluation II; ARDS: Acute respiratory distress syndrome; COVID-19: Coronavirus disease 2019; FiO 2 : Fraction of inspired oxygen; ICU: Intensive care unit; IL-6: Interleukin-6; IQR: Interquartile range; LIS: Lung injury score; NA: Not available; PaCO 2 : Partial pressure of carbon dioxide

None.